Donate

digestive disease week

Home»Posts tagged with»digestive disease week

Weight Loss Physical Activity Improve GERD

ORLANDO, Fla. — Participants in a weight-loss program experienced improvement in GERD symptoms with successful weight loss in a study presented at Digestive Disease Week.In a prospective cohort study, researchers evaluated weight, calorie intake and responses to a validated reflux disease questionnaire (RDQ) in 213 obese and overweight participants enrolled in a structured weight-loss program. […]

FUSE Colonoscopy Produced Better Adenoma Detection

ORLANDO, Fla. — Colonoscopies performed using a new, 330-degree colonoscope resulted in significantly improved detection and miss rates for adenomas compared with standard colonoscopes, according to data presented at Digestive Disease Week.In a prospective, multicenter, international study, researchers administered tandem colonoscopies via traditional forward-viewing (TFV) and full spectrum endoscopy (FUSE, EndoChoice) to 185 adult patients […]

Crohn’s Disease Surgery Common with Anxiety Depression Patients

ORLANDO, Fla. — Patients with Crohn’s disease and psychiatric comorbidities such as anxiety or depression are more likely to require disease-related surgery, according to data presented at Digestive Disease Week in Orlando.Researchers assessed the prevalence of major depressive disorder and anxiety among 5,405 patients with Crohn’s disease (CD) and 5,429 with ulcerative colitis (UC). All […]

No difference in IVF success rates in IPAA vs non-IPAA patients

ORLANDO, Fla. – A Mayo Clinic researcher said here at Digestive Disease Week that a patient who has undergone ileal pouch-anal anastomosis should not be discouraged from seeking to become pregnant.Sunanda V. Kane, MD, professor of medicine, division of gastroenterology and hepatology, Mayo Clinic, presented unpublished data on the success of in vitro fertilization (IVF) […]

Phase 3 Study Results Show Anti-TNF SIMPONI® Active Ulcerative Colitis

Phase 3 Study Results Show Anti-TNF SIMPONI® Active Ulcerative Colitis

Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults With Moderately to Severely Active Ulcerative Colitis   First Presentation of Phase 3 Data Shows Significant Improvements in Clinical Remission, Mucosal Healing and Quality of Life Measures after SIMPONI Induction Treatment New study findings show that subcutaneous induction regimens of the anti-tumor necrosis […]

Crohn’s Colitis Flare-Ups May Be Associated With Air Travel

Crohn’s Colitis Flare-Ups May Be Associated With Air Travel

Crohn’s Colitis Flare-Ups May Be Associated With Air Travel FRIDAY, May 25 (IDEAS) Individuals with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, could possibly be at greater probability for flare-ups whenever they take a flight or go to high altitudes for rock climbing or hiking, new research advises. This additional complications impacted individuals […]

Santarus Announces Presentation of UCERIS Phase III Extended Use

Santarus Announces Presentation of UCERIS Phase III Extended Use

About Ulcerative Colitis Ulcerative colitis is a form of inflammatory bowel disease (IBD) that produces inflammation and ulcers along the inside of the colon. The inflammation can interfere with the normal function of the colon, often causing cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements, which may also strongly affect quality of […]

UCB Commitment to Crohn’s Disease Community at Digestive Disease Week 2012

UCB Proudly Reinforces Long-Standing Commitment to Crohn’s Disease Community at Digestive Disease Week 2012 ATLANTA, May 18, 2012 /PRNewswire via COMTEX/ UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological disorders, is marking Digestive Disease Week (DDW) 2012 in San Diego by reinforcing […]

Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study

Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study

Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study May 10, 2011 Abbott Park, Illinois (NYSE: ABT) — Abbott’s HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific […]

No Guts Know Glory

IDEAS Kids

IDEAS Kids

IBD Adventures